The Emprint™ HP ablation generator gives you more volume, with a single antenna.1

Using our patented Thermosphere™ technology, the Emprint™ HP ablation generator enables a minimally invasive procedure with:​

  • Large ablations, with up to 40 percent more volume compared to the original Emprint™ ablation system1
  • Proven spherical shape,2,3 giving you flexibility in antenna placement approach4
  • Consistent ablative margins greater than 5 mm4,†​
  • Scalability, allowing you to create both small and large ablation zones1

Value Analysis Brief​

A comprehensive overview of the Emprint™ ablation system.

View Now

Celebrating 25 years of ablation at Medtronic

We've been the leading partners of life-transforming technology for the past 25 years — and we couldn't have done it without you. Together, we'll help to alleviate pain, restore health, and extend life, today and tomorrow.

Order Information
CARTHP Emprint™ HP Ablation Cart   Box 1
CAGENHP Emprint™ HP Ablation Generator with Thermosphere™ Technology   Box 1
CA15L1 Emprint™ Short Percutaneous Antenna with Thermosphere™ Technology Large Spherical Ablation Zone 15 cm Box 1
CA20L1 Emprint™ Standard Percutaneous Antenna with Thermosphere™ Technology Large Spherical Ablation Zone 20 cm Box 1
CA30L1 Emprint™ Long Percutaneous Antenna with Thermosphere™ Technology Large Spherical Ablation Zone 30 cm Box 1
CAPUMP1 Emprint™ Ablation Pump   Box 1
CA190RC1 Emprint™ Ablation Reusable Cable 190 cm Box 1
RFASW Emprint™ Footswitch   Each 1
RTP20 Cool-tip™ RF Ablation Remote Temperature Probe E Series 20 cm Each 1
CA15L2 Emprint™ short percutaneousaAntenna with Thermosphere™ technology 15 cm Each 1
CA20L2 Emprint™ standard percutaneous antenna with Thermosphere™ technology 20 cm Each 1
CA30L2 Emprint™ long percutaneous antenna with Thermosphere™ technology 30 cm Each 1

Order Information


Eradicate non-resectable liver tumors4

Our patented Thermosphere™ technology can help lower the chance of local tumor recurrence by achieving large ablation volumes with predictable margins.7​

Our purpose-built innovation helps you eradicate your patients’ non-resectable liver tumors and preserve more of their healthy parenchyma4,6 — because their future depends on both.

Video still of Emprint HP ablation system

Emprint™ animation video​

Thermosphere video animation highlighting increased wattage of HP and the app.

Watch video

Emprint™ HP zone chart app

The Emprint™ HP ablation zone app puts the ablation setting details you need in the palm of your hand. Comprehensive ex vivo and in vivo ablation zone reference values are included.

Available for both Android and iPhone users.​

Our product portfolio 

Emprint™ ablation system with Thermosphere™ technology​

The Emprint™ ablation system enables a minimally invasive procedure with recovery time,11,12 high accuracy,7 and predictable margins.7

Emprint™ percutaneous antennas with Thermosphere™ technology​

The Emprint™ ablation generator is compatible with the Emprint™ percutaneous ablation antenna. Our patented Thermosphere™ technology creates a predictable ablation zone focused at the end of the antenna, with no significant influence from varying tissue conditions.7

Antennas are available in three lengths: short (15 cm), standard (20 cm) and long (30 cm).​

Clinical evidence

Multi-institutional analysis of outcomes for Thermosphere™ microwave ablation treatment of colorectal liver metastases:
The SMAC study​

Conclusion: Thermosphere™ microwave ablation (T-MWA) is a safe and effective treatment for colorectal liver metastases (CLM) with no biliary complications reported in more than 200 ablated lesions. local tumor progression-free survival (LTPFS) is affected by lesion size at ablation, number of lesions, minimal ablation margin, and intra-segment progression. Chemotherapy before ablation (CBA) modifies kinetics growth of the lesions but deteriorates ablation margins and does not significantly impact local tumor progression-free survival.​

Authors: Francesco De Cobelli et al.
Published by: Eur Radiol, 2022.


Emprint™ ablation system: Clinically relevant ablative margin

Evaluation of microwave ablation of liver malignancy with enabled constant spatial energy control to achieve a predictable spherical ablation zone.

Study design: A single-center, retrospective cohort study comparing 48 subjects with hepatic tumors (total 56 tumors) treated with Emprint™ ablation system with Thermosphere™ technology to subjects who underwent conventional high-frequency MWA (n=20) or low-frequency MWA (n=20).​

Authors: Thomas J. Vogl et al.
Published by: Int. Journal of Hyperthermia, 2018.

Patient resources

Find patient information about liver tumors.​

  • †Independent study was performed using the 100 W Emprint™ ablation generator. A total of 56 tumors ablated with the Emprint™ ablation system had a median size of 1.4 cm (range 0.4 to 3.7 cm).

  • 1. IFU: Emprint™ Ablation System with Thermosphere™ Technology User Guide. Part Number PT00118305. Rev. 2020-03.

  • 2. Imajo K, Tomeno W, Kanezaki M, et al. New microwave ablation system for unresectable liver tumors that forms large, spherical ablation zones. J Gastroenterol Hepatol. 2018;33(12):2007–2014.

  • 3. Zaidi N, Okoh A, Yigitbas H, et al. Laparoscopic microwave thermosphere ablation of malignant liver tumors: An analysis of 53 cases. J Surg Oncol. 2016;113(2):130–134.

  • 4. Vogl TJ, Basten LM, Nour-Eldin A, et al. Evaluation of microwave ablation of liver malignancy with enabled constant spatial energy control to achieve a predictable spherical ablation zone. Int J Hyperthermia. 2018;34(4):492–500.

  • 5. Ierardi AM, Mangano A, Floridi C, et al. A new system of microwave ablation at 2450 MHz: preliminary experience. Updates Surg. 2015;67(1):39–45.

  • 6. Takahashi H, Kahramangil B, Berber E. Local recurrence after microwave thermosphere ablation of malignant liver tumors: results of a surgical series. Surgery. 2018;163(4):709–713. doi:10.1016/j.surg.2017.10.026.

  • 7. De Cobelli F, Marra P, Ratti F, et al. Microwave ablation of liver malignancies: comparison of effects and early outcomes of percutaneous and intraoperative approaches with different liver conditions. Med Oncol. 2017;34(4):49.